Clinical Trial Search

Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 2 participants

Primary: Overall Response Rate (ORR) in the Anaplastic Thyroid Cancer (ATC) Cohort — 56; 56; 53; 53 Percentage of Participants

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 1; 2; 0; 1 participants

Primary: Overall Response Rate (ORR) in Each Arm Receiving Targeted Therapy Based on Relevant Genomic Alterations — 10.3; 0; 7.1; 0 percentage of participants

Primary: Dose Limiting Toxicity — 0; 0; 0; 0 Participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 4; 3; 7; 3 Participants

Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg

Primary: Overall Survival — 13.43; 7.62 months

Primary: Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events — 100.0; 100.0; 100.0; 99.8 Percentage of…

Primary: Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Drug-Related AEs, Deaths, Discontinuation of Study Drug Due to AE, Dose-Limiting…

Primary: Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days — 57; 29 Participants — p=0.7186

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Number of Participants With Successful Bone Marrow Engraftment — 1; 15; 1 Participants

Primary: Number of Participants With Grade 4 TMI Toxicity — 0; 0; 0; 2 Participants

Primary: Maximum Tolerated Dose (MTD) — 20 mg/day

Primary: Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level — 1; 3; 0; 2 Participants

Primary: Percentage of Participants With Objective Response (OR) — 0 Percentage of participants

Primary: Stage 1: Dosing Schedule of Low-dose Cyclophosphamide — 6; 6 Participants

Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants

Primary: Overall Response Rate (ORR) — 5.6; 0.0; 11.3; 14.3 percentage of participants

Primary: Composite Success Rate — 100; 75; 84 Percentage of participants

Primary: Clinical Responses in Patients With Metastatic Ocular Melanoma — 0; 0; 9; 7 Participants

Primary: Total Number of Adverse Events. — 2 Adverse events

Primary: Overall Response Rate (Confirmed) — 1; 1 Participants

Primary: Safety and Tolerability Measured by Assessing Serious Adverse Events (SAEs)and Adverse Events (AEs) — 1; 3; 2; 2 Participants

Primary: Evaluate the Safety and Tolerability of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas With Wild-type (WT) TP53 Who Are Refractory to or Intolerant…

Primary: Number of Participants With Overall Response Advanced or Metastatic Pancreatic Cancer. — 0; 3 Participants

Primary: Objective Response Rate (ORR) by Investigator — 12; 14 percentage of participants

Primary: Dose Limiting Toxicities (DLT) in the Trial Subjects. — 0; 0; 0; 0 DLT